Patients with cardiovascular risk factors and stable coronary artery disease, with a fasting total cholesterol level =5 mmol/l.
Conditions
Interventions
Trade Name: Lipitor 10 mg Tablets
Product Name: Lipitor 10mg
Pharmaceutical Form: Film-coated tablet
Trade Name: Lipitor 80mg Tablets
Product Name: Lipitor 80mg
Pharmaceutical Form: Film-coated table
Sponsors
Chief Scientitst Office
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Stable coronary artery disease Patients aged 18-80 years Total choleterol >5 mmol/l Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Acute coronary syndrome within 3 months Previously documented statin-intolerance Hepatic dysfunction (Childs Pugh score >5) Significant comorbidity associated with reduce longevity Participation in another clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To assess whether, compared to 10 mg atorvastatin, a strategy of intensive lipid lowering with 80 mg atorvastatin to LDL-cholesterol levels of =2 mmol/l has a significant net effect on i) platelet-monocyte binding, ii) monocyte phenotype and inflammatory function, iii) CD40-CD40ligand interactions, and iv) the balance of pro-and anti-inflammatory cytokines, chemokines and adhesion molecules.;Secondary Objective: To establish whether a linear relationship exists between lipid-lowering and the degree of anti-inflammatory effect.;Primary end point(s): Measures of inflammation and biomarkers at three months of randomised treatment | — |
Countries
United Kingdom
Outcome results
None listed